Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H22ClN5O |
Molecular Weight | 419.907 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(NC(=O)C(C3=NC4=CC=CC=C4N3)=C2N[C@@H]5CN6CCC5CC6)C=C1
InChI
InChIKey=MOVBBVMDHIRCTG-LJQANCHMSA-N
InChI=1S/C23H22ClN5O/c24-14-5-6-16-15(11-14)21(25-19-12-29-9-7-13(19)8-10-29)20(23(30)28-16)22-26-17-3-1-2-4-18(17)27-22/h1-6,11,13,19H,7-10,12H2,(H,26,27)(H2,25,28,30)/t19-/m1/s1
Molecular Formula | C23H22ClN5O |
Molecular Weight | 419.907 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17255282Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22106282 |
https://www.ncbi.nlm.nih.gov/pubmed/22244109
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17255282
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22106282 |
https://www.ncbi.nlm.nih.gov/pubmed/22244109
CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. CHIR-124 potently and selectively inhibits Chk1 in vitro. CHIR-124 interacts synergistically with topoisomerase poisons (e.g., camptothecin or SN-38) in causing growth inhibition in several p53-mutant solid tumor cell lines. CHIR-124 abrogates the SN-38-induced S and G(2)-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. CHIR-124 treatment can restore the level of cdc25A protein, which is normally targeted by Chk1 for degradation following DNA damage, indicating that Chk1 signaling is suppressed in the presence of CHIR-124. In an orthotopic breast cancer xenograft model, CHIR-124 potentiates the growth inhibitory effects of irinotecan by abrogating the G(2)-M checkpoint and increasing tumor apoptosis. The combination of gemcitabine and CHIR-124 in the multicellular tumor spheroid model enhanced the sensitivity to the gemcitabine antiproliferative effect in correlation with an increase in DNA damage and apoptosis. CHK1 inhibition by Chir-124 sensitizes HCT116 cancer cells to radiation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4630 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17255282 |
3.0E-4 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17255282
In vivo antitumor activity was studied in severe combined immunodeficient
mice harboring MDA-MD-435 tumor xenografts. CHIR-124 (10 or 20 mg/kg) was given orally four times daily _ 6 on days 2 to 7 in captisol.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17255282
CHIR-124 potently and selectively inhibits Chk1 in vitro (IC50 = 0.0003 mkM). CHIR-124 interacts synergistically with topoisomerase poisons (e.g., camptothecin or SN-38) in causing growth inhibition in several p53-mutant solid tumor cell lines as determined by isobologram or response surface analysis. CHIR-124 abrogates the SN-38-induced S and
G2-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. The abrogation of the G2-Mcheckpoint and induction of apoptosis by CHIR-124 are enhanced by the loss of p53.We have also shown that CHIR-124 treatment can restore the level of cdc25A protein, which is normally targeted by Chk1for degradation following DNA damage, indicating that Chk1 signaling is suppressed in the presence of CHIR-124.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:24:53 GMT 2023
by
admin
on
Sat Dec 16 08:24:53 GMT 2023
|
Record UNII |
5K64W8EU3E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB06852
Created by
admin on Sat Dec 16 08:24:53 GMT 2023 , Edited by admin on Sat Dec 16 08:24:53 GMT 2023
|
PRIMARY | |||
|
5K64W8EU3E
Created by
admin on Sat Dec 16 08:24:53 GMT 2023 , Edited by admin on Sat Dec 16 08:24:53 GMT 2023
|
PRIMARY | |||
|
405168-58-3
Created by
admin on Sat Dec 16 08:24:53 GMT 2023 , Edited by admin on Sat Dec 16 08:24:53 GMT 2023
|
PRIMARY | |||
|
135399748
Created by
admin on Sat Dec 16 08:24:53 GMT 2023 , Edited by admin on Sat Dec 16 08:24:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |